Search

Displaying results 5001 - 5010 of 8698 in total
  1. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. … COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease.

  2. Drug

    Parnaparin

    go.drugbank.com/drugs/DB09260
    Approved

    Parnaparin is an heparin of low molecular weight with antithrombotic effects.

  3. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  4. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).

  5. Drug

    Gefarnate

    go.drugbank.com/drugs/DB12079
    Investigational

    Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  6. Drug

    Black widow spider antivenin (equine)

    go.drugbank.com/drugs/DB14113
    Approved

    Black widow spider (_Latrodectus mactans_) antivenin is a treatment for black widow spider bites derived from the serum of healthy horses immunized against black widow spider venom.[L12792]

  7. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  8. Drug

    Dimethylthiambutene

    go.drugbank.com/drugs/DB01444
    ExperimentalIllicit

    Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug.

  9. Drug

    Poly(lactic acid)

    go.drugbank.com/drugs/DB15037
    ApprovedInvestigationalWithdrawn

    Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).

  10. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity